The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISA 2024 | The role of the hematologist and cardiologist in treating patients with amyloidosis
Ronald Witteles, MD, Stanford University, Stanford, CA, shares his thoughts on the importance of close collaboration between cardiologists and hematologists when treating patients with light chain (AL) amyloidosis, and further explains the value of collaboration across other multidisciplinary teams (MDTs). This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting for Pfizer, Alnylam, BridgeBio, Novo Nordisk, Astra Zeneca, Janssen, Alexion
